Towards an understanding of the treatment and mechanistic effects of tominersen
GENERATION HD1 (NCT03761849) was a randomised, multicentre, double-blind, Phase III, placebo-controlled trial designed to evaluate the safety and efficacy of tominersen in adults with manifest Huntington’s disease. In March 2021, dosing was stopped in GENERATION HD1 following a recommendation from the independent data monitoring committee. This presentation outlines data from the GENERATION HD1 core analysis and exploratory post hoc analysis which further our mechanistic understanding of tominersen and support next steps for the tominersen programme.
{{assetTitle}}
{{assetDescription}}
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.